The strategic transaction is projected to conclude in the second quarter of 2026, signaling a significant expansion for the French pharmaceutical group in the rare oncology sector.
Financial terms of the agreement
Servier has reached an agreement to purchase Day One Biopharmaceuticals at a cash price of $21.50 per share. The deal values the company’s total equity at approximately $2.5 billion.
This offer reflects a 68% premium over the stock’s closing price on March 5, 2026, and an 86% increase relative to the one-month volume-weighted average price as of that date.
Strategic alignment and portfolio growth
By integrating Day One—a California-based firm dedicated to pediatric cancer therapies—Servier advances its “2030 ambition” to provide solutions for rare cancers and neurological conditions.
The acquisition bolsters Servier’s oncology pipeline with multiple programs ranging from early-stage research to Phase III clinical trials. A primary focus of this synergy involves advancing treatments for pediatric low-grade glioma, addressing critical gaps in current medical care.
Corporate profiles
-
Servier: An international group based in France with operations in over 130 countries and a workforce of 20,000. Its 2024-25 fiscal revenue was recorded at roughly $8 billion.
-
Day One Biopharmaceuticals: A commercial-stage biotech company centered on developing innovative medicines for children diagnosed with cancer.
Executives from both organizations anticipate that the combined expertise will accelerate the delivery of scientific innovations to patients facing high unmet medical needs.